Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Cardiol Therapeutics Inc

CRDL ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.80

▲ +5.26%

Market Cap $208.81M · Vol 402.81K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$208.81M

Micro Cap

Div Yield

N/A

EPS Growth

-40.46%

YoY

RSI (14)

91.08

Momentum

Beta

0.82

vs Market

52W High

$1.82

1.10% below

52W Low

$0.88

104.55% above

Volume

402.81K

Avg 172.80K

P/B

7.35

Price-to-book

ROE

N/A

Return on equity

Free Float

97.05%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Cardiol Therapeutics Inc (CRDL) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CRDL pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+26.76%

+56.52%

+31.39%

+73.08%

YTD

+88.72%

+34.33%

+90.60%

-38.36%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-24,642,138.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-121.91% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	7.35
P/FCF	N/A
EPS Growth	-40.46%
Outstanding Shares	115.88M

Technical Indicators

50-Day SMA	$1.18
200-Day SMA	$1.14
RSI (14)	91.08
Beta	0.82
52-Week High	$1.82
52-Week Low	$0.88

Volume Today	402.81K
Avg Daily Volume (30D)	172.80K
Relative Volume	2.33x
Volatility (10D)	51.93
Volatility (30D)	65.76
Free Float	97.05%

Analyst Consensus

BUY

Current Price $1.80

Mean Target $8.00

52W Low$0.88 52W High$1.82

Current

Target

$0.88 $1.82

Current Analyst target

+344.44% upside potential · 4 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00M0GNQ75

ISINCA14161Y2006

CountryCanada

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 13, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.